Cagol, Alessandro http://orcid.org/0000-0002-7703-0553
Fuertes, Nuria Cerdá
Stoessel, Marc
Barakovic, Muhamed
Schaedelin, Sabine
D’Souza, Marcus
Würfel, Jens
Brandt, Alexander U.
Kappos, Ludwig
Sprenger, Till
Naegelin, Yvonne
Kuhle, Jens
Granziera, Cristina
Papadopoulou, Athina http://orcid.org/0000-0002-0367-1008
Funding for this research was provided by:
Eurostars (E!113682 HORIZON2020)
Schweizerische Multiple Sklerose Gesellschaft
University of Basel
Article History
Received: 13 November 2022
Revised: 12 December 2022
Accepted: 13 December 2022
First Online: 10 January 2023
Declarations
:
: Alessandro Cagol has nothing to disclose. Nuria Cerdá Fuertes has nothing to disclose. Mark Stössel has nothing to disclose. Muhamed Barakovic is an employee of Hays plc and a consultant for F. Hoffmann-La Roche Ltd. Sabine Schaedelin has nothing to disclose. Marcus D’Souza is CEO of Neurostatus-UHB Ltd. He has received travel support from Bayer AG, Biogen, Teva Pharmaceuticals and Sanofi Genzyme and research support from the University Hospital Basel. Jens Würfel is currently an employee of F. Hoffmann-La Roche Ltd. He served on scientific advisory boards of Actelion, Biogen, Genzyme-Sanofi, Novartis, and Roche. He is or was supported by grants of the EU (Horizon2020), German Federal Ministeries of Education and Research (BMBF) and of Economic Affairs and Energy (BMWI). Alexander Ulrich Brandt is cofounder and shareholder of technology startups Motognosis and Nocturne UG. He is named as inventor on several patent applications describing MS serum biomarkers, perceptive visual computing and retinal image analysis. Ludwig Kappos: Institutional research support: steering committee, advisory board, consultancy fees: Actelion, Bayer HealthCare, Biogen, Bristol Myers Squibb, Genzyme, Janssen, Japan Tobacco, Merck, Novartis, Roche, Sanofi, Santhera, Shionogi, and TG Therapeutics, speaker fees: Bayer HealthCare, Biogen, Merck, Novartis, Roche, and Sanofi; support of educational activities: Allergan, Bayer HealthCare, Biogen, CSL Behring, Desitin, Genzyme, Merck, Novartis, Roche, Pfizer, Sanofi, Shire, and Teva; license fees for Neurostatus products; and grants: Bayer HealthCare, Biogen, European Union, Innosuisse, Merck, Novartis, Roche, Swiss MS Society, and Swiss National Research Foundation. Till Sprenger: Grants from EFIC-Grünenthal, Novartis Pharmaceuticals Switzerland, the Swiss MS Society, and the Swiss National Research Foundation. Institution received payments for steering committee/consultation and speaking activities from Actelion, Biogen Idec, Bristol Myers Squibb, Electrocore, Eli Lilly, Janssen, Merck Serono, Mitsubishi Pharma, Novartis, Roche, Sanofi, and Teva. Yvonne Naegelin’s employer, the University Hospital Basel, received payments for lecturing from Celgene GmbH and Teva Pharma AG that were exclusively used for research support, not related to this study. Jens Kuhle received speaker fees, research support, travel support, and/or served on advisory boards by Swiss MS Society, Swiss National Research Foundation (320030_189140/1), University of Basel, Progressive MS Alliance, Bayer, Biogen, Celgene, Merck, Novartis, Octave Bioscience, Roche, Sanofi. Cristina Granziera: The University Hospital Basel (USB), as the employer of C.G., has received the following fees which were used exclusively for research support: (i) advisory board and consultancy fees from Actelion, Genzyme-Sanofi, Novartis, GeNeuro and Roche; (ii) speaker fees from Genzyme-Sanofi, Novartis, GeNeuro and Roche; (iii) research support from Siemens, GeNeuro, Roche. The University of Basel (USB), as the employer of Athina Papadopoulou has received speaker-fees from Sanofi-Genzyme, Eli Lilly and Teva and fees for advisory boards (Lundbeck Schweiz AG, AbbVie AG). Athina Papadopoulou has received travel support from Bayer AG, Teva, Lilly and F. Hoffmann-La Roche. Her research was/is being supported by the University and the University Hospital of Basel, the Swiss Multiple Sclerosis Society, the ‘Stiftung zur Förderung der gastroenterologischen und allgemeinen klinischen Forschung sowie der medizinischen Bildauswertung’, the "Freie Akademische Gesellschaft" Basel and the Swiss National Science Foundation (Project number: P300PB_174480).